Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting
Conclusionsnbsp;nbsp; CYP2C9 polymorphisms leading to decreased enzyme activity show a modest impact on the risk of mild hypoglycaemia attacks during oral antidiabetic treatment, with a significant association in patients treated with gliclazide. Content Type Journal ArticlePages 1-7DOI 10.1007/s00228-011-1078-4Authors Osman Gökalp, Medical Faculty, Department of Pharmacology, Dicle University, Diyarbakir, TurkeyArzu Gunes, Department of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala, SwedenHakan Çam, Medical Faculty, Department of Internal Medicine, Süleyman Demirel University, Isparta, TurkeyErkan Cure, Medical Faculty, Department of Internal Medicine, Süleyman Demirel University, Isparta, TurkeyOsman Aydın, Medical Faculty, Department of Interna...

The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury
Abstractnbsp;nbsp;Heart disease and stroke account for 65% of the deaths in people with diabetes mellitus (DM). DM and hyperglycemia cause systemic inflammation, endothelial dysfunction, a hypercoagulable state with impaired fibrinolysis and increased platelet degranulation, and reduced coronary collateral blood flow. DM also interferes with myocardial protection afforded by preconditioning and postconditioning. Newer anti-diabetic agents should not only reduce serum glucose and HbA1c levels, but also improve cardiovascular outcomes. The older sulfonylurea agent, glyburide, abolishes the benefits of ischemic and pharmacologic preconditioning, but newer sulfonylurea agents, such as glimepiride, may not interfere with preconditioning. GLP-1 analogs and sitagliptin, an oral dipeptidyl...